NCT04262856 (ARC-7) is a Phase 2 clinical trial of Domvanalimab in Non Small Cell Lung Cancer, sponsored by Arcus Biosciences, Inc..

Who is sponsoring NCT04262856?

NCT04262856 is sponsored by Arcus Biosciences, Inc..

What drugs are being tested in NCT04262856?

Interventions in NCT04262856: Domvanalimab, Etrumadenant, Zimberelimab.

What condition does NCT04262856 study?

NCT04262856 studies Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer.

Is NCT04262856 still recruiting?

NCT04262856 is currently completed. Last updated 26 August 2025.

Last reviewed 2025-08-26 · How we verify

NCT04262856: ARC-7

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Completed Phase 2 Last updated 26 August 2025

What this trial tests

Phase 2 trial testing Domvanalimab in Non Small Cell Lung Cancer in 151 participants. Completed in 9 July 2025.

Timeline

28 May 2020

Primary endpoint
5 June 2025

9 July 2025

Quick facts

Lead sponsor	Arcus Biosciences, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	151
Start date	28 May 2020
Primary completion	5 June 2025
Estimated completion	9 July 2025
Sites	44 locations across Hong Kong, Taiwan, South Korea, Canada, Australia, Singapore, United States

Drugs / interventions tested

Domvanalimab — full drug profile →
Etrumadenant — full drug profile →
Zimberelimab — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Nonsquamous Non Small Cell Lung Cancer — all drugs for Nonsquamous Non Small Cell Lung Cancer →
Squamous Non Small Cell Lung Cancer — all drugs for Squamous Non Small Cell Lung Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Arcus Biosciences, Inc. — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Nonsquamous Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, et al · · 2022 · cited 253× · PMID 35222404 · DOI 10.3389/fimmu.2022.823618
Antibodies to watch in 2022.
Kaplon H, Chenoweth A, Crescioli S, Reichert JM. · · 2022 · cited 245× · PMID 35030985 · DOI 10.1080/19420862.2021.2014296
CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · · 2023 · cited 230× · PMID 36859386 · DOI 10.1186/s12943-023-01733-x
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. · · 2021 · cited 166× · PMID 34367161 · DOI 10.3389/fimmu.2021.699895
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.
Joller N, Anderson AC, Kuchroo VK. · · 2024 · cited 159× · PMID 38354701 · DOI 10.1016/j.immuni.2024.01.010
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y, Wang X, Jin T, Tian Y, et al · · 2020 · cited 133× · PMID 33122640 · DOI 10.1038/s41392-020-00348-8

Verify or expand the search:

Other trials of Domvanalimab

Trials testing the same drug.

NCT07283848 — Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma · Phase 2 · withdrawn
NCT05724563 — Domvanalimab and Zimberelimab in Advanced Liver Cancers · Phase 2 · active not recruiting
NCT05130177 — Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma · Phase 2 · active not recruiting
NCT05211895 — A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi · Phase 3 · recruiting
NCT04791839 — Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patient · Phase 2 · active not recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Arcus Biosciences, Inc. trials

Trials by the same sponsor.

NCT06919991 — Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) · Phase 1 · completed
NCT06608927 — Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ad · Phase 3 · active not recruiting
NCT06004921 — A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers · Phase 1 · completed
NCT05999513 — A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers · Phase 1 · completed
NCT05411146 — A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in t · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04262856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arcus Biosciences, Inc.
Last refreshed: 26 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing